Quantcast
Last updated on April 19, 2014 at 13:20 EDT

Latest Montelukast Stories

2014-03-25 00:23:18

DUBLIN, March 25, 2014 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/rq8jml/investigation) has announced the addition of the "Investigation Report on China Montelukast Market" [http://www.researchandmarkets.com/research/rq8jml/investigation ] report to their offering. <start_newscom> (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) There are over 30 million people suffering from seasonal asthma of different...

2013-12-18 08:29:11

Generic Erosion of Market Leaders Will Be Offset by the First Once-Daily LABA/ICS Combination and Emerging Anticytokine Agents, According to Findings from Decision Resources BURLINGTON, Mass., Dec. 18, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the drug market for asthma will remain relatively flat through 2022. Currently, the market is driven by maintenance therapies that...

2012-11-21 08:23:31

NEW YORK, Nov. 21, 2012 /PRNewswire/ -- As in the previous quarter, proton-pump inhibitors, antipsychotics and statins remain in the top-selling therapeutic categories. Merck's asthma and allergy preventive Singulair predictably drops out of the top five drugs due to Q3 patent loss. Top Five Drugs by Sales, Q3 2012 Drug Name Sales ($000) % Change (previous quarter) --- ------- Nexium...

2012-09-05 14:23:39

CINCINNATI, Sept. 5, 2012 /PRNewswire/ -- HealthWarehouse.com, Inc. (OTC: HEWA) a leading VIPPS accredited retail mail-order pharmacy, today announced its financial results for the first quarter ended March 31, 2012. In the first quarter of 2012, the Company's quarterly net sales increased to $3,153,607 from $2,284,552, up 38% compared to the same period in 2011. Selling, general and administrative expenses (SG&A) increased by $730,780 in the first quarter of 2012 compared to the same...

2012-08-21 02:27:18

NEW YORK, Aug. 21, 2012 /PRNewswire/ -- Drugs.com, the leading online clinical drug resource, today released second quarter 2012 U.S. prescription sales data for the top 100 drugs. Proton-pump inhibitors, antipsychotics, asthma therapeutics and statins remain the top-selling categories. Plavix and Seroquel dipped in the second quarter due to loss of patent protection. Other top brands such as Singulair, Actos and Diovan are also due to be impacted by year's end. Top Five Drugs by Sales,...

2012-08-07 02:28:40

PITTSBURGH, Aug. 7, 2012 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Mylan Pharmaceuticals has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Montelukast Sodium Tablets, 10 mg, the generic version of Merck's Singulair® Tablets. Mylan also received final FDA approval for its ANDA for Montelukast Sodium Chewable Tablets, 4 mg and 5 mg, the generic version of Merck's Singulair®...

2012-08-06 02:25:58

HUNTSVILLE, Ala., Aug. 6, 2012 /PRNewswire/ -- Qualitest Pharmaceuticals today confirmed that it has launched a generic version of Singulair (montelukast sodium) Tablets and Chewable Tablets, following the expiration of the last patent that provides Merck U.S. market exclusivity. Qualitest will begin shipping the product immediately. Montelukast Sodium Tablets are labeled for use in treating symptoms of asthma and allergic rhinitis. The total combined sales for Montelukast...

2012-07-18 02:26:44

NEW YORK, July 18, 2012 /PRNewswire/ -- Drugs.com, the leading online clinical drug resource, today released first quarter 2012 U.S. prescription sales data for the top 100 drugs. Blood-thinners, proton-pump inhibitors, antipsychotics and asthma therapeutic categories continue to remain top sellers. Top Five Drugs by Sales, Q1 2012 Drug Name Sales ($000) % Change (previous quarter) --------- ----------- ------------------...

2011-05-06 07:32:05

(Ivanhoe Newswire) -- A new study shows a rarely-prescribed drug is easier to use and may be just as effective as treatment with inhalers. Asthma affects about 300 million people worldwide. It is a chronic condition characterized by inflammation of the airways that leads to wheezing, coughing, chest tightness and shortness of breath. Researchers followed 650 patients with chronic asthma for two years. They found leukotriene receptor antagonists (LTRAs) were just as successful at managing the...

2011-05-05 13:01:28

A rarely prescribed asthma drug is easier to use and just as effective as conventional treatment with inhalers, according to a new study led by the University of East Anglia (UEA). Publishing tomorrow in the New England Journal of Medicine, the researchers followed 650 patients with chronic asthma for two years. They found that tablets called leukotriene receptor antagonists (LTRAs) managed the disease equally successfully as steroid inhalers and other 'preventer' inhalers when used in...